SCHEMBL15675671

SCHEMBL15675671

CCn1cc(Cl)c2cc(S(N)(=O)=O)ccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.44
PIK3CG P48736 1/20 0.44
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
CA9 Q16790 7/20 0.42
CA12 O43570 5/20 0.42
CA2 P00918 5/20 0.42
CA1 P00915 4/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
VCAM1 P19320 1/20 0.42
HTR7 P34969 1/20 0.42
HTR6 P50406 1/20 0.42
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15675769 0.84 ALDH1A1 (0.50) ALDH1A1GAAPIK3CGKDM4ELMNA
SCHEMBL15676094 0.82 ALDH1A1 (0.49) ALDH1A1GAAPIK3CGKDM4ELMNA
SCHEMBL24824867 0.76 PTGER4 (0.44) ALDH1A1KDM4ELMNAHTR7HTR6
SCHEMBL15704199 0.74 CACNB4 (0.41) ALDH1A1GAAKDM4ELMNAHTR7
SCHEMBL24823829 0.73 CYP19A1 (0.43) ALDH1A1GAAKDM4ELMNAHTT
SCHEMBL9127426 0.72 ALDH1A1 (0.57) ALDH1A1GAAKDM4ELMNAHTT
SCHEMBL14061517 0.71 ALDH1A1 (0.53) ALDH1A1LMNAHTR6
SCHEMBL15701668 0.71 RORA (0.38) HTR6MAPT
SCHEMBL23599328 0.67 CA2 (0.58) CA9CA12CA2CA1CA4
SCHEMBL15675664 0.67 CA2 (0.42) ALDH1A1PIK3CGCA9CA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346795-B2 Substituted sulfonamides useful as antiapoptotic Bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-24 US disclosed
US-9346795-B2 Substituted sulfonamides useful as antiapoptotic Bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-24 US disclosed
US-9346795-B2 Substituted sulfonamides useful as antiapoptotic Bcl inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-05-24 US disclosed
EP-2714681-B1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-06-24 EP disclosed
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-15 US disclosed
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-15 US disclosed
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135318-A1 SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS BCL2, BAX, BCL2A1 ALDH1A1 2963/4885GAA 1774/4885PIK3CG 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.